MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1002/pds.70390

Медицинская библиотека · Pharmacoepidemiology and drug safety · 2026

Early Identification of Differentiation Syndrome During ATRA and Arsenic Therapy in Pediatric NHR-APL: Insights From a 14-Year Multicenter Cohort.

Fan Zhong, Yang Liang-Chun, Chen Yi-Qiao, Wan Wu-Qing, Mai Hui-Rong, Yang Li-Hua, Lan He-Kui, Zhou Dun-Hua, Li Wan-Li, Guo Bi-Yun, He Fei, Liao Liu-Hua, Chen Hui-Qin, Zhen Zi-Jun, He Xiang-Ling, Feng Xiao-Qin, Chen Guo-Hua, Ji Xun-Qi, Chen Mo, Li Qiao-Ru, Long Xing-Jiang, Tian Chuan, Fu Ying, Huang Xiu-Ya, Luo Jie-Si, Huang Dan-Ping, Wang Li-Na, Li Yu, Li Bin, Luo Xue-Qun, Huang Li-Bin, Tang Yan-Lai, Zhang Xiao-Li

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

The combination of all-trans retinoic acid (ATRA) with arsenic trioxide (ATO) has dramatically improved the cure rate of acute promyelocytic leukemia (APL). However, differentiation syndrome (DS) remains a significant cause of early mortality in APL patients. This severe complication typically occurs during induction therapy with ATRA and/or ATO. Early prediction and timely intervention are crucial to reducing DS-related mortality. This study aimed to identify risk factors for DS and develop a predictive model tailored to children with non-high-risk (NHR) APL.

METHODS

We conducted a multicenter retrospective analysis of 166 pediatric NHR-APL patients treated between 2011 and 2024. Clinical characteristics were compared between DS and non-DS groups. Logistic regression was used to identify independent predictors, and a nomogram was developed based on these variables. The model was evaluated using the area under the curve (AUC) and decision curve analysis (DCA).

RESULTS

Seventeen patients (10.2%) developed DS during induction. Multivariate analysis identified five independent risk factors: female sex, non-chemotherapy group, BCR subtype 3, elevated peripheral promyelocyte proportion (≥ 44%), and platelet count (≥ 20 × 109/L). The predictive nomogram achieved an AUC of 0.89 in the training set and 0.75 in the validation set. DCA demonstrated favorable clinical utility of the model.

CONCLUSIONS

We developed and validated the first nomogram for predicting DS in pediatric NHR-APL. This tool enables early risk stratification and may guide clinical decision-making to reduce early mortality.

Для цитирования: Fan Zhong, Yang Liang-Chun, Chen Yi-Qiao, Wan Wu-Qing, Mai Hui-Rong, Yang Li-Hua, Lan He-Kui, Zhou Dun-Hua, Li Wan-Li, Guo Bi-Yun, He Fei, Liao Liu-Hua, Chen Hui-Qin, Zhen Zi-Jun, He Xiang-Ling, Feng Xiao-Qin, Chen Guo-Hua, Ji Xun-Qi, Chen Mo, Li Qiao-Ru, Long Xing-Jiang, Tian Chuan, Fu Ying, Huang Xiu-Ya, Luo Jie-Si, Huang Dan-Ping, Wang Li-Na, Li Yu, Li Bin, Luo Xue-Qun, Huang Li-Bin, Tang Yan-Lai, Zhang Xiao-Li. Early Identification of Differentiation Syndrome During ATRA and Arsenic Therapy in Pediatric NHR-APL: Insights From a 14-Year Multicenter Cohort.. Pharmacoepidemiology and drug safety. 2026. DOI: 10.1002/pds.70390.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.